| pubmed-article:12457028 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0278678 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C1880659 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:12457028 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:12457028 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12457028 | pubmed:dateCreated | 2002-11-28 | lld:pubmed |
| pubmed-article:12457028 | pubmed:abstractText | To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). | lld:pubmed |
| pubmed-article:12457028 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12457028 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12457028 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12457028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12457028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12457028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12457028 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12457028 | pubmed:issn | 0030-2414 | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:GomezFF | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:DouillardJ... | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:NégrierSS | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:ChevreauCC | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:LesimpleTT | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:LinassierCC | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:DelvaRR | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:GeoffroisLL | lld:pubmed |
| pubmed-article:12457028 | pubmed:author | pubmed-author:BennounaJJ | lld:pubmed |
| pubmed-article:12457028 | pubmed:copyrightInfo | Copyright 2003 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:12457028 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12457028 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:12457028 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12457028 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12457028 | pubmed:pagination | 25-7 | lld:pubmed |
| pubmed-article:12457028 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:meshHeading | pubmed-meshheading:12457028... | lld:pubmed |
| pubmed-article:12457028 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12457028 | pubmed:articleTitle | A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. | lld:pubmed |
| pubmed-article:12457028 | pubmed:affiliation | Centre René Gauducheau, Nantes, France. j-bennouna@nantes.fnclcc.fr | lld:pubmed |
| pubmed-article:12457028 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12457028 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12457028 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:12457028 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
